Provided by Tiger Fintech (Singapore) Pte. Ltd.

Atara Biotherapeutics

7.25
+0.39005.69%
Post-market: 7.250.00000.00%16:05 EDT
Volume:28.31K
Turnover:200.31K
Market Cap:41.76M
PE:-0.32
High:7.25
Open:6.97
Low:6.67
Close:6.86
Loading ...

Company Profile

Company Name:
Atara Biotherapeutics
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
159
Office Location:
2380 Conejo Spectrum Street,Suite 200,Thousand Oaks,California,United States
Zip Code:
91320
Fax:
- -
Introduction:
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Directors

Name
Position
Pascal Touchon
Director,President and Chief Executive Officer
Ronald C. Renaud, Jr.
Chair of the Board
Ameet Mallik
Director
Beth Seidenberg
Director
Carol Gallagher
Director
Eric L. Dobmeier
Director
Maria Grazia Roncarolo
Director
Matthew K. Fust
Director
Roy Baynes
Director
William Heiden
Director

Shareholders

Name
Position
Pascal Touchon
Director,President and Chief Executive Officer
Amar Murugan
Senior Vice President, General Counsel
Kristin Yarema
Senior Vice President, Chief Commercial Officer
Utpal Koppikar
Executive Vice President, Chief Financial Officer
Jakob Dupont
Executive Vice President, Global Head of Research and Development